Table 2.
Multivariable-Adjusted Hazard Ratios for 25-Hydroxyvitamin Insufficiency and Event-Free, Lymphoma-Specific, and Overall Survival
| Variable | No. | Distribution (%) | Adjustment Factor(s) | Event-Free Survival |
Lymphoma-Specific Survival |
Overall Survival |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Events | % Events | HR | 95% CI | No. of Events | % Events | HR | 95% CI | No. of Events | % Events | HR | 95% CI | ||||
| DLBCL | IPI, treatment* | ||||||||||||||
| Sufficient | 178 | 48.1 | 50 | 28.1 | 1.00 | Reference | 27 | 15.2 | 1.00 | Reference | 31 | 17.4 | 1.00 | Reference | |
| Insufficient | 192 | 51.9 | 82 | 42.7 | 1.41 | 0.98 to 2.04 | 63 | 32.8 | 2.16 | 1.33 to 3.51 | 69 | 35.9 | 1.99 | 1.27 to 3.13 | |
| P | .07 | .002 | .003 | ||||||||||||
| TCL | IPI | ||||||||||||||
| Sufficient | 30 | 42.9 | 16 | 53.3 | 1.00 | Reference | 8 | 26.7 | 1.00 | Reference | 8 | 26.7 | 1.00 | Reference | |
| Insufficient | 40 | 57.1 | 33 | 82.5 | 1.94 | 1.04 to 3.61 | 20 | 50.0 | 2.26 | 0.99 to 5.17 | 21 | 52.5 | 2.38 | 1.04 to 5.41 | |
| P | .04 | .05 | .04 | ||||||||||||
| MCL | MIPI | ||||||||||||||
| Sufficient | 45 | 63.4 | 27 | 60.0 | 1.00 | Reference | 11 | 24.4 | 1.00 | Reference | 11 | 24.4 | 1.00 | Reference | |
| Insufficient | 26 | 36.6 | 18 | 69.2 | 1.09 | 0.59 to 2.01 | 8 | 30.8 | 1.35 | 0.53 to 3.39 | 8 | 30.8 | 1.35 | 0.53 to 3.39 | |
| P | .78 | .53 | .53 | ||||||||||||
| FL | FLIPI, FLIII, treatment† | ||||||||||||||
| Sufficient | 175 | 61.4 | 65 | 37.1 | 1.00 | Reference | 5 | 2.9 | 1.00 | Reference | 10 | 5.7 | 1.00 | Reference | |
| Insufficient | 110 | 38.6 | 39 | 35.5 | 1.07 | 0.71 to 1.62 | 4 | 3.6 | 0.90 | 0.23 to 3.49 | 9 | 8.2 | 1.52 | 0.60 to 3.88 | |
| P | .75 | .88 | .38 | ||||||||||||
| Post-FL | Stage, PS | ||||||||||||||
| Sufficient | 68 | 62.4 | 25 | 36.8 | 1.00 | Reference | 4 | 5.9 | 1.00 | Reference | 4 | 5.9 | 1.00 | Reference | |
| Insufficient | 41 | 37.6 | 14 | 34.2 | 0.98 | 0.51 to 1.89 | 4 | 9.8 | 2.76 | 0.58 to 13.1 | 4 | 9.8 | 2.76 | 0.58 to 13.1 | |
| P | .95 | .20 | .20 | ||||||||||||
| All other | Stage, PS | ||||||||||||||
| Sufficient | 51 | 63.0 | 21 | 41.2 | 1.00 | Reference | 7 | 13.7 | 1.00 | Reference | 8 | 15.7 | 1.00 | Reference | |
| Insufficient | 27 | 27.0 | 14 | 51.9 | 1.15 | 0.57 to 2.32 | 7 | 25.9 | 1.73 | 0.58 to 5.17 | 10 | 37.0 | 2.08 | 0.79 to 5.49 | |
| P | .71 | .33 | .14 | ||||||||||||
Abbreviations: HR, hazard ratio; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; TCL, T-cell lymphoma; MCL, mantle cell lymphoma; MIPI, Mantle Cell International Prognostic Index; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; FLIII, follicular lymphoma grade 3; PS, performance status.
*
Immunochemotherapy v all other therapy.
†
Rituximab-based therapy, other chemotherapy v observation.